Press Releases

Read Regulatory and non-regulatory press releases

  • All
  • Non-Regulatory
  • Regulatory
Regulatory

Oncology Venture advancing towards next milestone in its clinical development of IXEMPRA®.

Regulatory

Oncology Venture can inform that the last trading day of the Subscription Rights is now 19 November 2019, following the extension of subscription period until the 21 November of the current rights issue

Regulatory

Oncology Venture extends the subscription period of the current rights issue

Regulatory

Oncology Venture advancing towards next milestone in its clinical development of 2X-121.

Regulatory

Oncology Venture reaches new development milestone with Dovitinib.

Regulatory

Oncology Venture is streamlining its communications by publishing press releases in English only going forward.

Regulatory

The Board of Oncology Venture resolves to conduct a rights issue of new shares, and publishes prospectus regarding the rights issue

Regulatory

Minutes of Extraordinary General Meeting

Regulatory

OV increases its share capital due to warrant exercise

Regulatory

NOTICE TO CONVENE EXTRAORDINARY GENERAL MEETING

Regulatory

Oncology Venture presents positive data at ESMO on DRP as   a response predictor for 5-FU treatment in colorectal cancer

Regulatory

Oncology Venture provides further information on the terms for a proposed rights issue

Regulatory

Oncology Venture appoints new CEO and CFO and proposes rights issue to facilitate a focused commercial strategy

Regulatory

Oncology Venture publishes Interim Report for the period January – June 2019

Regulatory

FDA grants IDE approval to use Oncology Venture’s LiPlaCis DRP for patient selection in a pivotal Phase 3 study

Regulatory

Oncology Venture – First day of trading in investor warrants

Regulatory

New company takes over Certified Advisor role to OV

Regulatory

Oncology Venture gets European patent on its AI powered method to find patients who will benefit from LiPlaCis

Regulatory

Oncology Venture provides financial details regarding its recent acquisition of additional ownership in dovitinib

Regulatory

Oncology Venture increases its ownership in dovitinib